Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions ...

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the ...

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...

He said it becomes more common as people age. By the age of 80, people have about a 10% risk of having AFib.Vesely said age is a risk factor, but so are obesity, hypertension, thyroid disease and ...

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated ...

Considered a disease of middle-aged and older adults until the late 20th century, type 2 diabetes has risen markedly ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...